Cargando…

A novel multi-biomarker combination predicting relapse from long-term remission after discontinuation of biological drugs in rheumatoid arthritis

Biological disease modifying anti-rheumatic drugs (bDMARDs) show dramatic treatment efficacy in rheumatoid arthritis (RA). Long-term use of bDMARDs, however, has disadvantages such as high costs and infection risk. Therefore, a methodology is needed to predict any future RA relapse. Herein, we repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagatani, Katsuya, Sakashita, Eiji, Endo, Hitoshi, Minota, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531387/ https://www.ncbi.nlm.nih.gov/pubmed/34675298 http://dx.doi.org/10.1038/s41598-021-00357-9

Ejemplares similares

Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis
por: Sakashita, Eiji, et al.
Publicado: (2022)

Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission
por: Kameda, Hideto, et al.
Publicado: (2021)

Increase of a wide range of bioactive substances in an active phase of neuro-Sweet disease
por: Kusaka, Hiroi, et al.
Publicado: (2020)

Ruptured Baker's Cyst in Rheumatoid Arthritis
por: Nakamura, Jun, et al.
Publicado: (2018)

Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis
por: O’Neil, Liam J., et al.
Publicado: (2021)

Raoultella planticola Bacteremia in a Patient with Early Gastric Cancer
por: Yamamoto, Shotaro, et al.
Publicado: (2017)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Remission in Rheumatoid Arthritis
por: Shammas, Rania M., et al.
Publicado: (2010)

Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
por: Alivernini, Stefano, et al.
Publicado: (2016)

Fatal Thrombotic Microangiopathy and Posterior Reversible Encephalopathy Syndrome in a Patient with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis
por: Yamamoto, Shotaro, et al.
Publicado: (2021)

Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis
por: Honne, Kyoko, et al.
Publicado: (2015)

Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission
por: Tasaki, Shinya, et al.
Publicado: (2018)

A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis
por: Ma, M. H. Y., et al.
Publicado: (2020)

Molecular remission at T cell level in patients with rheumatoid arthritis
por: Inamo, Jun, et al.
Publicado: (2021)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Rheumatoid Arthritis Relapse and Remission – Advancing Our Predictive Capability Using Modern Imaging
por: Terslev, Lene, et al.
Publicado: (2021)

Independent association of HLA-DPB1*02:01 with rheumatoid arthritis in Japanese populations
por: Furukawa, Hiroshi, et al.
Publicado: (2018)

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Umbilical Plaque in Psoriatic Arthritis
por: Nagashima, Takao, et al.
Publicado: (2017)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Correction: Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Publicado: (2016)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
por: Bolge, Susan C, et al.
Publicado: (2015)

Comparison of Biologic Discontinuation in Patients With Elderly‐Onset Versus Younger‐Onset Rheumatoid Arthritis
por: Richter, Michael D., et al.
Publicado: (2019)

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission
por: Ben Abdelghani, Kawther, et al.
Publicado: (2022)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
por: Nagy, György, et al.
Publicado: (2015)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Rheumatoid arthritis fibroblast-like synoviocytes show the upregulation of myeloid cell specific transcription factor PU.1 and B cell specific transcriptional co-activator OBF-1, and express functional BCMA
por: Itoh, Kenji, et al.
Publicado: (2012)

Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan
por: Mori, Shunsuke, et al.
Publicado: (2011)

Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature
por: Mangoni, Arduino A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_34922f15sqlkm925g2ln6a0k7o